7 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinibnon-small cell lung carcinomaActive, not recruitingNot stated2026-10-08NCT04764188
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology ProductsBranch Vein Occlusion, Embolism and Thrombosis, Venous Thrombosis, cardiovascular disorder, central retinal vein occlusion, diabetic macular edema, eye disorder, retinal disorder, retinal vein occlusion, thrombotic disease, vascular disorderActive, not recruitingNot stated2026-10-02NCT05476926
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic MedicinesSkin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, bone disorder, musculoskeletal system disorder, psoriasis, psoriatic arthritis, skin disorder, spondylitis, vertebral column disorderRecruitingPhase 32026-09-17NCT06671483
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset EpilepsyDrug Resistant Epilepsy, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, epilepsy, focal epilepsy, nervous system disorder, visual epilepsyActive, not recruitingPhase 2 / Phase 32026-08-13NCT06309966
Long-term Safety and Tolerability of BHV-7000Drug Resistant Epilepsy, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, epilepsy, focal epilepsy, nervous system disorder, visual epilepsyEnrolling by invitationPhase 22026-05-01NCT06443463
A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditionsnarcolepsy-cataplexy syndromeRecruitingPhase 2 / Phase 32026-03-05NCT05816382
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple SclerosisCNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Multiple Sclerosis, Primary Progressive, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic progressive multiple sclerosis, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorderActive, not recruitingPhase 32026-02-23NCT04035005